800 Boylston Street, 24th Floor
101 articles with Flex Pharma
Flex Pharma Announces Overwhelming Support to Date for the Proposed Merger with Salarius Pharmaceuticals but More Votes are Needed to Complete the Merger
Special Meeting of Stockholders Adjourned Until July 12, 2019
Flex Pharma Announces that ISS and Glass Lewis Recommend Shareholders Vote “FOR” All Agenda Items relating to Flex’s Strategic Merger with Salarius Pharmaceuticals
Flex Pharma, Inc. announced that Institutional Shareholder Services Inc. and Glass Lewis recommend that shareholders vote FOR all agenda items before or at Flex Pharma’s June 14 Special Shareholders Meeting.
Flex Pharma, Inc., announced its financial results for the three months ended March 31, 2019.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flex Pharma, Inc. - FLKS
Under the terms of the proposed transaction, FLKS stockholders will own 19.9% of the combined company upon completion of the transaction.
Flex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer
Lead Candidate in Clinical Trial for Treating Ewing Sarcoma
On June 13, 2018, the Company announced that it was ending its ongoing Phase 2 clinical trial investigations of FLX-787 in Motor Neuron Disease
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Flex Pharma, Newell, and PolarityTE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Flex Pharma, Inc., Newell Brands, Inc., and PolarityTE, Inc.
Flex Pharma, Inc. today announced its financial results for the three months ended June 30, 2018.
Federman & Sherwood announces that on June 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Flex Pharma, Inc.
Flex Pharma announced in a Corporate Update that it is closing an ongoing Phase II clinical trial of FLX-787 in ALS and CMT while shifting its strategy to focus on other approaches.
Flex Pharma, Inc. today announced that the Company is ending its ongoing Phase 2 clinical trial investigations of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).
-- Positive Anti-Cramping Effect of FLX-787 Reported in Recent MS study -- -- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing -- Conference Call Scheduled Today at 9:00 a.m. ET
Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis
Flex Pharma Inc. announced positive topline data for FLX-787 from its exploratory Phase 2 trial in MS patients with frequent muscle cramps/spasms and spasticity.
Flex Pharma Inc. reported financial results for the year ended December 31, 2017 and provided an update on its clinical development and corporate activities.
A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com.
The randomized, placebo-controlled, blinded, cross-over study is designed to evaluate the safety and efficacy of FLX-787.
The Company will host a conference call and webcast at 8:45 a.m. ET to discuss third quarter 2017 financial results and provide a business update.
Dr. Tung is the scientific co-founder of Concert Pharmaceuticals, where he serves as President and Chief Executive Officer. Prior to Concert, Dr. Tung was a founding scientist at Vertex, a pharmaceutical company.
ALS Phase 2 Trial Currently Underway